Abstract
Nanobiotechnology involves the engineering of systems, devices, and materials which can be implemented within a physiological system on a scale between 1-100nm. Nanometric materials have significant potential to exhibit unprecedented capacities for interacting with specific molecular, organellar, and cellular components of the brain via their novel optical, electronic, and structural properties. Hence, they are poised to establish new paradigms for the future of brain cancer treatment. Nanooncology is currently the most important arena in nanomedicine, and the application of nanoscale innovations in neuroscience will bring forth diagnostic and therapeutic inventions unseen hitherto in the assessment and treatment of brain cancer. Nanobiosensors, magnetic nanoparticles, and nanoparticle-chemotherapy conjugates are specific avenues within brain cancer treatment that illustrate the credible utilization of sophisticated nanobiotechnology in neurooncology. Nanotechnologically-based medical solutions are slowly progressing from the laboratory bench to clinical trials. This review aims to highlight the data that bridges the gap between laboratory benchtop and hospital bedside, as well as to illustrate potential platforms through which nanomedicine may be integrated into standardized treatment protocols against various forms of neurological cancers. Categories: Miscellaneous, General Surgery, Oncology
Highlights
Tumor malignancies originating in the central nervous system (CNS) account for only 2% of all cancers but are correlated with a high mortality and morbidity rate
More than 20% of animals treated with the nanoparticle-doxorubicin conjugate showed long-term remission [15]
We have presented findings to suggest that nanotechnology will serve as a viable candidate for potential treatments of various brain cancers, reducing both untoward morbidity and mortality from this devastating disease
Summary
Tumor malignancies originating in the central nervous system (CNS) account for only 2% of all cancers but are correlated with a high mortality and morbidity rate. The ability to develop specific nano-chemo agents that are under precise directives to release the drug within the tumor in an exclusive manner is imperative for successful treatment of future brain tumor patients in that it enables the clinicians to decrease the side-effects of the chemoagent by ensuring its administration only to the cancerous tissue within the brain The development of these nano-sized medicinal elements is multifaceted in that it dictates a trajectory through basic science research, translational and clinical medicine, and industry partners (Figure 3). The median survival after recurrence was 13.4 months (95% CI=10.6-16.2 months) and from the time of initial diagnosis was 23.2 months [37] The success of this innovative clinical trial paves the way for safe and effective thermotherapy of cancerous brain tumors with the utilization of newly engineered MNPs (Figure 6). Credited Plank, et al [38]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
